Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 1

Interventions

Nivolumab 5pembrolizumab 4Temozolomide 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Rituximab 2Radiosurgery 2Paclitaxel 2Neoadjuvant Therapy 2Ipilimumab 2Gemcitabine 2Fluorodeoxyglucose F18 2Dexamethasone 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Biopsy 2Bevacizumab 2venetoclax 1theanine 1temsirolimus 1tafasitamab 1sugemalimab 1senicapoc 1semaglutide 1sacituzumab govitecan 1prednylidene 1pirtobrutinib 1perampanel 1paricalcitol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × azeliragon × 30 days × Clear all
NCT06831526 2026-05-29

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Washington University School of Medicine

Phase EARLY_PHASE1 Recruiting
12 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡